Bringing antibodies from early development to clinic and beyond

Emily Event News Leave a Comment

Monoclonal antibodies (MAbs) are inherently sensitive to handle. In an effort to improve the specificity of oncology treatment, many pharma and biotech worked on combining these MAbs with cytotoxins to kill cancer cells. While it is challenging to synthesis these Antibody-drug conjugate (ADC) in lab, it is even harder to mass produce these macromolecules to run it through clinical trials …